撑起骨质疏松症管理：一个新起点？

Shoring Up Osteoporosis Management: A Fresh Start?

机构信息

From the Nellis Family Medicine Residency, Nellis AFB, Las Vegas, NV.

出版信息

J Am Board Fam Med. 2024 May-Jun;37(3):490-493. doi: 10.3122/jabfm.2024.240060R0.

DOI:10.3122/jabfm.2024.240060R0

Abstract

Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.

摘要

合成代谢类骨药物，如甲状旁腺激素受体激动剂（特立帕肽和abaloparatide）和硬化蛋白抑制性单克隆抗体（romosozumab），在预防有或无严重骨质疏松症的女性发生临床显著骨折和/或椎体骨折方面优于双膦酸盐类药物。